The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Akari Therapeutics and WuXi XDC Partner to Advance Novel Cancer Therapy

Key Facts

1Akari Therapeutics announced a strategic partnership with WuXi XDC to advance its novel ADC payload targeting RNA splicing.

2The partnership aims to accelerate the Investigational New Drug (IND) filing by late 2026.

Akari Therapeutics has entered into a strategic partnership with WuXi XDC to accelerate the development of its novel Antibody-Drug Conjugate (ADC) technology. The collaboration focuses on advancing Akari's unique payload that targets RNA splicing, a promising approach in oncology. By leveraging WuXi XDC's integrated platform, Akari aims to streamline the manufacturing and development processes for its lead therapeutic candidates. The primary goal of this partnership is to facilitate the filing of an Investigational New Drug (IND) application by late 2026. This move strengthens Akari's oncology pipeline and provides a clear operational roadmap toward future clinical trials. While the timeline for clinical entry remains long, analysts view this as a positive step for the company's long-term growth prospects.